Shen L - Search Results

1

Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer.

Zhou Z, Chen ZW, Yang XH, Shen L, Ai XH, Lu S, Luo QQ. Zhou Z, et al. Among authors: shen l. J Exp Clin Cancer Res. 2012 Apr 26;31(1):34. doi: 10.1186/1756-9966-31-34. J Exp Clin Cancer Res. 2012. PMID: 22537906 Free PMC article.

2

[Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer].

Shen L, Li ZM, Lu S. Shen L, et al. Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):442-6. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21875485 Chinese.

3

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Shen L, Li Z, Shen S, Niu X, Yu Y, Li Z, Liao M, Chen Z, Lu S. Shen L, et al. Among authors: shen s. Lung Cancer. 2012 Dec;78(3):193-200. doi: 10.1016/j.lungcan.2012.08.012. Epub 2012 Sep 15. Lung Cancer. 2012. PMID: 22985911

4

An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.

Ai X, Shen S, Shen L, Lu S. Ai X, et al. Among authors: shen s, shen l. Biochimie. 2015 May;112:111-20. doi: 10.1016/j.biochi.2015.03.003. Epub 2015 Mar 11. Biochimie. 2015. PMID: 25769414

5

Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases.

Yu Y, Jian H, Shen L, Zhu L, Lu S. Yu Y, et al. Among authors: shen l. Eur J Surg Oncol. 2016 Nov;42(11):1714-1719. doi: 10.1016/j.ejso.2016.02.247. Epub 2016 Mar 8. Eur J Surg Oncol. 2016. PMID: 27017272

6

Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma.

Yu Y, Ding Z, Jian H, Shen L, Zhu L, Lu S. Yu Y, et al. Among authors: shen l. Cancer Med. 2016 Sep;5(9):2323-31. doi: 10.1002/cam4.821. Epub 2016 Jul 25. Cancer Med. 2016. PMID: 27456862 Free PMC article.

7

Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.

Shen L, Niu X, Jian H, Xu Y, Yu Y, Lu S. Shen L, et al. Lung Cancer. 2017 Sep;111:43-50. doi: 10.1016/j.lungcan.2017.07.001. Epub 2017 Jul 4. Lung Cancer. 2017. PMID: 28838396

8

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.

Li Z, Shen L, Ding D, Huang J, Zhang J, Chen Z, Lu S. Li Z, et al. Among authors: shen l. J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25. J Thorac Oncol. 2018. PMID: 29704675 Free article.

9

First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.

Shen L, Qiang T, Li Z, Ding D, Yu Y, Lu S. Shen L, et al. Cancer Med. 2020 May;9(10):3310-3318. doi: 10.1002/cam4.2972. Epub 2020 Mar 13. Cancer Med. 2020. PMID: 32167664 Free PMC article.

10

Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing.

Yu Y, Shen L, Ji W, Lu S. Yu Y, et al. Among authors: shen l. Ann Transl Med. 2021 Jan;9(2):140. doi: 10.21037/atm-20-7702. Ann Transl Med. 2021. PMID: 33569442 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,363 results

Search Page

Filters